华大九天发布上半年业绩，归母净利润306.79万元，同比下降91.90%

Core Viewpoint - BGI Genomics (301269.SZ) reported a revenue of 502 million yuan for the first half of 2025, reflecting a year-on-year growth of 13.01% [2] - The net profit attributable to shareholders decreased by 91.90% to 3.0679 million yuan [2] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 18.621 million yuan, showing a year-on-year reduction in losses of 63.66% [2] - Basic earnings per share were reported at 0.0057 yuan [2] Financial Performance - Revenue for the reporting period reached 502 million yuan, marking a 13.01% increase compared to the previous year [2] - Net profit attributable to shareholders was 3.0679 million yuan, down 91.90% year-on-year [2] - The company reported a net loss of 18.621 million yuan after excluding non-recurring items, which is a 63.66% improvement in loss reduction compared to the same period last year [2] - Basic earnings per share stood at 0.0057 yuan [2]